Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

azilsartan medoxomil

EDARBI

azilsartan medoxomil (EDARBI) is a type-1 angiotensin ii receptor antagonist. Associated with Takeda. Current US regulatory status: approved.

FDA: approved EMA: approved Cardiovascular system (C09) C09CA09
US status approved
Patents linked 20
Pipeline programs 7
News articles 0
Drug details — azilsartan medoxomil
US status
approved
Class
Cardiovascular system (C09)
Route
—
Patents
20
Programs
7
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

azilsartan medoxomil (EDARBI) is a type-1 angiotensin ii receptor antagonist. Associated with Takeda. Current US regulatory status: approved.

Key facts

INN azilsartan medoxomil
Brand EDARBI
Mechanism Type-1 angiotensin II receptor antagonist
Therapeutic class Cardiovascular system (C09)
Formulation TABLET
ATC code C09CA09
Originator Takeda

Mechanism of action

Type-1 angiotensin II receptor antagonist

Approval history

Authority Status Date
FDA approved —
EMA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Azilsartan Medoxomil Phase 3 · Takeda · Hypertension
  2. Azilsartan Medoxomil and amlodipine Phase 3 · Takeda · Hypertension
  3. Azilsartan medoxomil and olmesartan Phase 3 · Takeda · Hypertension
  4. Azilsartan medoxomil with or without add-on chlorthalidone Phase 3 · Takeda · Hypertension
  5. Azilsartan medoxomil/placebo Phase 3 · Takeda · Essential Hypertension
  6. Azilsartan medoxomil (TAK-491) Phase 1 · Takeda · Hypertension
  7. Azilsartan Medoxomil Approved · Takeda · Essential Hypertension

Related & competitor drugs

Browse all drugs
  1. alirocumab Cardiovascular system (C10)
  2. aliskiren Cardiovascular system (C09)
  3. bempedoic acid Cardiovascular system (C10)
  4. bosentan Cardiovascular system (C02)
  5. dofetilide Cardiovascular system (C01)
  6. dopamine hydrochloride Cardiovascular system (C01)

Related patents

Browse patents Takeda patent hub

  1. US 12421188

    Heterocyclic compound and use thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12415782

    Heterocyclic compound and use thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12409210

    CNS delivery of therapeutic agents

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12391765

    Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12391760

    Method of treating primary sclerosing cholangitis

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12384770

    Heterocyclic compound

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12383587

    AAV triple-plasmid system

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12378256

    Heterocyclic compound

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12358879

    Heterocyclic compound

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12337020

    Bacteriophage compositions

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12319940

    Methods for purification of arylsulfatase A

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12290531

    Compositions targeting BCMA and methods of use thereof

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12286456

    Purification of virus like particles

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12281073

    Substituted piperidine compound and use thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12202797

    Method for producing pyrrole compound

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12201683

    Methods for preventing dengue and hepatitis a

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12188948

    Metabolite biomarkers for diseases associated with the contact activation system

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12171777

    Methods of making a cyclic dinucleotide

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12171832

    Methods of treating ulcerative colitis

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12168041

    Methods and compositions for CNS delivery of arylsulfatase A

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is azilsartan medoxomil?

azilsartan medoxomil (EDARBI) is a type-1 angiotensin ii receptor antagonist. Associated with Takeda. Current US regulatory status: approved.

What is the brand name for azilsartan medoxomil?

EDARBI is a marketed brand name for azilsartan medoxomil. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of azilsartan medoxomil?

azilsartan medoxomil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.